Batu Biologics Appoints Biopharmaceutical Executive Dr. Alan Lewis As Chairman Of The Board

Batu Biologics, a San Diego biotechnology company dedicated towards the development of its cancer angiogenesis-targeting immunotherapeutic product, ValloVax, announced today the appointment of Dr. Alan Lewis as Chairman of the Board of Directors.

"We are enthusiastic to have the opportunity to work with Dr. Lewis in his new capacity as Chairman of the Board. Given the recent filing of an IND with the FDA to initiate a dose escalating Phase I/II clinical trial in lung cancer, we believe that having a Chairman with the industry experience of Dr. Lewis will strategically position Batu Biologics for entry into partnerships and collaborations with others in the field," Said Samuel Wagner, President and CEO of Batu Biologics.

Suggested Articles

The FDA slapped a partial clinical hold on the phase 2/3 study of Inovio’s COVID-19 vaccine because it has “additional questions” about the trial.

Preclinical inflammatory disease biotech Ilias Biologics has grabbed a $20.6 million funding round as it eyes a 2021 human test of its leading asset.

Aligos Therapeutics is shooting for a $100 million IPO to help drive its early work on a functional cure for chronic hepatitis B as well as COVID-19.